Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy
Renin-angiotensin system (RAS) inhibitors (RASi)—widely prescribed for the treatment of
cardiovascular diseases—have considerable potential in oncology. The RAS plays a crucial
role in cancer biology and affects tumor growth and dissemination directly and indirectly by
remodeling the tumor microenvironment. We review clinical data on the benefit of RASi in
primary and metastatic tumors and propose that, by activating immunostimulatory pathways,
these inhibitors can enhance immunotherapy of cancer.
cardiovascular diseases—have considerable potential in oncology. The RAS plays a crucial
role in cancer biology and affects tumor growth and dissemination directly and indirectly by
remodeling the tumor microenvironment. We review clinical data on the benefit of RASi in
primary and metastatic tumors and propose that, by activating immunostimulatory pathways,
these inhibitors can enhance immunotherapy of cancer.
Renin-angiotensin system (RAS) inhibitors (RASi)—widely prescribed for the treatment of cardiovascular diseases—have considerable potential in oncology. The RAS plays a crucial role in cancer biology and affects tumor growth and dissemination directly and indirectly by remodeling the tumor microenvironment. We review clinical data on the benefit of RASi in primary and metastatic tumors and propose that, by activating immunostimulatory pathways, these inhibitors can enhance immunotherapy of cancer.
![](/scholar/images/qa_favicons/sciencemag.org.png)
以上显示的是最相近的搜索结果。 查看全部搜索结果